Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
First patients dosed in the EVERLAST-A Phase 2a trial of ORKA-001, with data expected in 2H 2026
Are there any regulatory or reimbursement considerations that could influence the trial’s commercial potential once data are released?
What are the potential implications for ORKA’s valuation if the Phase 2a data meet or miss expectations?
How might the trial’s enrollment rate and patient population impact the likelihood of achieving positive data outcomes?
26 days ago